T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Ingevity
NGVT
$2.61B
| $34.7M | ﹤0.01% |
484,407
-16,109
| -3% | -$1.23M |
|
1127
Entrada Therapeutics
TRDA
$289M
| $34.6M | ﹤0.01% |
+2,020,637
| New | +$49M |
|
1128
Kulicke & Soffa
KLIC
$5.06B
| $34.6M | ﹤0.01% |
570,750
+43,253
| +8% | +$2.47M |
|
1129
Alaska Air
ALK
$5.28B
| $34.5M | ﹤0.01% |
661,327
-140,173
| -17% | -$7.59M |
|
1130
Seagate
STX
$218B
| $34.4M | ﹤0.01% |
304,710
-664
| -0.2% | -$64.5K |
|
|
PFHD
1131
DELISTED
Professional Holding Corp. Class A Common stock
PFHD
| $34.3M | ﹤0.01% |
1,790,774
-54,036
| -3% | -$1.03M |
|
1132
Utah Medical Products
UTMD
$229M
| $34.3M | ﹤0.01% |
342,675
+61,290
| +22% | +$6.25M |
|
1133
Procept Biorobotics
PRCT
$1.25B
| $34.1M | ﹤0.01% |
1,403,071
+62,087
| +5% | +$2.3M |
|
|
BLFY
1134
DELISTED
Blue Foundry Bancorp
BLFY
| $34.1M | ﹤0.01% |
2,330,210
+524,836
| +29% | +$7.56M |
|
1135
Best Buy
BBY
$18.4B
| $34M | ﹤0.01% |
334,939
-13,823
| -4% | -$1.57M |
|
1136
KeyCorp
KEY
$24.9B
| $33.8M | ﹤0.01% |
1,460,339
-105,110
| -7% | -$2.44M |
|
1137
SOPHiA GENETICS
SOPH
$638M
| $33.6M | ﹤0.01% |
2,382,304
+23,863
| +1% | +$352K |
|
1138
ThredUp
TDUP
$411M
| $33.6M | ﹤0.01% |
2,629,668
+209,847
| +9% | +$3.82M |
|
1139
RingCentral
RNG
$5.34B
| $33.5M | ﹤0.01% |
179,047
-6,605
| -4% | -$1.47M |
|
1140
Enbridge
ENB
$111B
| $33.4M | ﹤0.01% |
855,034
-35,367
| -4% | -$1.42M |
|
|
PPL
1141
PPL Corp
PPL
$26.9B
| $33.3M | ﹤0.01% |
1,108,716
-93,799
| -8% | -$2.71M |
|
1142
W.W. Grainger
GWW
$62.2B
| $33.3M | ﹤0.01% |
64,224
-3,161
| -5% | -$1.49M |
|
1143
Teladoc Health
TDOC
$1.24B
| $33.2M | ﹤0.01% |
361,899
+25,578
| +8% | +$3.06M |
|
|
LPRO
1144
DELISTED
Open Lending Corp
LPRO
| $33.1M | ﹤0.01% |
1,474,116
+1,425,357
| +2,923% | +$40.4M |
|
|
ARIS
1145
DELISTED
Aris Water Solutions
ARIS
| $33.1M | ﹤0.01% |
+2,554,196
| New | +$33.9M |
|
1146
Annexon
ANNX
$852M
| $33.1M | ﹤0.01% |
2,876,667
+1,151,996
| +67% | +$18.6M |
|
1147
SiTime
SITM
$21B
| $32.8M | ﹤0.01% |
111,970
+2,504
| +2% | +$656K |
|
|
GTLS
1148
DELISTED
Chart Industries
GTLS
| $32.7M | ﹤0.01% |
204,928
-484,517
| -70% | -$85.6M |
|
1149
Celanese
CE
$5.01B
| $32.4M | ﹤0.01% |
193,076
-14,095
| -7% | -$2.3M |
|
1150
Diageo
DEO
$53.1B
| $32.3M | ﹤0.01% |
146,681
+4,852
| +3% | +$995K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.